RxDoctor Payments Data

Kelly Tucker, MD

Cardiovascular Disease · Orange, CANPI 1356372643

Payments from drug & device makers

$16,459in general payments, 2019–2025

Across 318 payments — averaging $51.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$3K
  • Biotronik Inc.$2K
  • Impulse Dynamics (USA) Inc.$1K
  • Novartis$874
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$702
  • plus $6K from 35 others

What the payments were for

  • Consulting fees$2502%
  • Travel & lodging$5274%
  • Food & beverage$13,32293%
  • Education$2131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,459 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$689,683
Medicare patients
547
Services billed
6,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban315$368,285
EntrestoSacubitril/Valsartan258$309,645
XareltoRivaroxaban83$66,301
Repatha SureclickEvolocumab57$36,062
BrilintaTicagrelor29$17,939
Losartan Potassium748$11,069
SotalolSotalol Hcl363$8,281
Doxazosin Mesylate206$4,443
Amlodipine Besylate653$3,969
Klor-Con 10Potassium Chloride11$2,838
Sotalol AfSotalol Hcl59$2,367
Valsartan56$2,347
Carvedilol213$1,967
Cephalexin40$1,691
Furosemide154$1,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$312$368,285315 claims
NovartisEntresto$874$309,645258 claims
Johnson & JohnsonXarelto$210$66,30183 claims
AstraZenecaBrilinta$49$17,93929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →